|Day's Range||55.31 - 55.39|
|52 Week Range||45.54 - 55.39|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.15%|
Strattera, a drug for attention-deficit hyperactivity disorder, reported a 4% increase in revenues to $196.2 million in 1Q17, compared to $188.1 million in 1Q16.
Depending on where one looks, performances for mid-cap exchange-traded funds this year range from solid to spectacular. The SPDR S&P MidCap 400 ETF (NYSE: MDY ) is solid with a year-to-date gain of 3.1 ...
With the S&P 500 off about 8 percent to start the year, advisors and investors may be left thinking that an early case of election year volatility is afoot. Conventional wisdom dictates that stocks can ...